Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACCAPELA: Alemtuzumab + CHOP in Aggressive T-Cell Lymphomas
NCT00453427Phase 2Completed
- Sponsor
- Ontario Clinical Oncology Group
- Start
- Sep 2006
- Primary completion
- Jun 2013
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of alemtuzumab in peripheral T-cell lymphoma (PTCL), sponsored by Ontario Clinical Oncology Group. Started Sep 2006; status: completed.
02
Drugs
alemtuzumab
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT00453427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00453427.